Despite obvious benefits and reported reduction in knee pain, addiction and alcoholism, share of employers covering GLP-1s for weight loss has declined for the first time in three years from 57% to 53%. CVS Health released an analysis of Aetna commercial claims finding that GLP-1 users had lower medical spending and fewer hospitalizations, but higher pharmacy costs still outweighed those savings. "It's impacting our entire approach to managing spending," Phillip Fortson, a utilization analyst from a midwest BCBS plan, said about the drug. CVS's analysis (which included both Medicaid FFS and managed care prescriptions) estimates that GLP-1 net prices would need to fall to approximately $350 per month for medical savings to offset drug costs over three years. Meanwhile, the University of Pittsburgh released research reporting an ~84% relative decline in weight-loss GLP-1 prescriptions in four states that ended coverage, compared with ten states maintaining coverage. As an example, in 2027, Deloitte is replacing broad GLP-1 weight-loss coverage with a lifestyle support program that includes access to direct-from-manufacturer GLP-1 medications and a company contribution for each prescription. About 12% of the population takes GLP-1s. "we're not at mass effect, but we're approaching it," said Susan Wolver, associate professor of internal medicine at VCU in our conversation earlier this year about the cascading effect of GLPs. Access here in case you missed.
GLP Fallback, But Why?
Next
Next